Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which w...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 5, ...
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer ...
Gainers: OncoSec Medical ( ONCS ) +44% . BioRestorative Therapies BRTX +32% . Astria Therapeutics ( ATXS ) +13% . Certara ( CERT ) +12% . Kazia Therapeutics ( KZIA ) +11% . Losers: ZimVie ( ZIMV ) -45% . Cano Health ( CAN...
The U.S. Food and Drug Administration (FDA) accepted for review Amneal Pharmaceuticals ( NYSE: AMRX ) application seeking approval of a generic version of opioid overdose therapy Narcan. Amneal had filed Abbreviated New Drug Application (ANDA) for naloxone hydrochl...
Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q4 Non-GAAP EPS of $0.23 beats by $0.02 . Revenue of $610M (+13.6% Y/Y) beats by $30.07M . FY2023 Outlook : Net revenue of $2.25B to $2.35B vs. consensus of $2.31B and Adjusted diluted EPS of $0.40 to $0.50 vs. c...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan ® and is used in the treatmen...
‒ Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03 ‒ ‒ Q4 2022 Adjusted Net Income of $71 million (1) , Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.23 ‒ ‒ Full Y...
Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is $0.21 (+16.7% Y/Y) and the consensus Revenue Estimate is $579.93M (+8.0% Y/Y). Over the last 2 years, AMRX has beaten ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...